End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
100.50 CHF | +4.75% |
|
+4.25% | +2.84% |
02-11 | DSM-Firmenich to Sell Feed Enzymes Alliance JV Share to Partner for $1.55 Billion | DJ |
02-11 | Novonesis to buy DSM-Firmenich's stake in enzymes venture for $1.6 bln | RE |
Capitalization | 26.51B 27.43B 25.03B 22.08B 39.24B 2,380B 43.56B 298B 111B 989B 103B 101B 4,176B | P/E ratio 2024 * |
59.2x | P/E ratio 2025 * | 33.5x |
---|---|---|---|---|---|
Enterprise value | 29.36B 30.38B 27.72B 24.45B 43.46B 2,636B 48.24B 330B 122B 1,095B 114B 112B 4,625B | EV / Sales 2024 * |
2.29x | EV / Sales 2025 * | 2.16x |
Free-Float |
25.03% | Yield 2024 * |
2.51% | Yield 2025 * | 2.57% |
Last Transcript: DSM-Firmenich
1 day | +4.75% | ||
1 week | +4.25% | ||
Current month | +1.70% | ||
1 month | +5.66% | ||
3 months | -4.60% | ||
6 months | -16.25% | ||
Current year | +2.84% |







Director | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 31/12/2019 | |
Ralf Schmeitz
DFI | Director of Finance/CFO | - | 31/08/2023 |
Ipek Ozsuer
CTO | Chief Tech/Sci/R&D Officer | 45 | 30/04/2023 |
Manager | Title | Age | Since |
---|---|---|---|
Thomas Leysen
CHM | Chairman | 64 | 31/01/2023 |
Director/Board Member | 63 | 31/01/2023 | |
André Pometta
BRD | Director/Board Member | 60 | 31/01/2023 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.82% | 0 M€ | +15.09% | - | |
0.51% | 0 M€ | +6.14% | - | |
0.22% | 0 M€ | -.--% | - | |
0.2% | 0 M€ | -.--% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+4.75% | +4.25% | +9.03% | - | 27.43B | ||
+0.50% | +1.04% | +18.43% | +48.00% | 1,019B | ||
0.00% | 0.00% | +0.50% | +117.14% | 240B | ||
-0.76% | -7.43% | +6.21% | +10.67% | 135B | ||
+0.05% | -0.91% | +62.81% | +245.74% | 121B | ||
+0.25% | -1.06% | +61.54% | -5.94% | 81.47B | ||
+0.42% | +1.57% | +1.15% | +18.81% | 76.39B | ||
+0.53% | -0.32% | +106.45% | +559.60% | 47.77B | ||
+0.90% | -0.57% | +11.59% | +70.50% | 32.72B | ||
+0.55% | -2.30% | -33.57% | -59.05% | 29.89B | ||
Average | +0.72% | -0.62% | +24.41% | +111.72% | 181.04B | |
Weighted average by Cap. | +0.37% | +0.44% | +20.52% | +76.50% |
2024 * | 2025 * | |
---|---|---|
Net sales | 12.81B 13.25B 12.09B 10.67B 18.96B 1,150B 21.05B 144B 53.42B 478B 49.66B 48.68B 2,018B | 13.43B 13.9B 12.68B 11.19B 19.88B 1,206B 22.07B 151B 56.02B 501B 52.07B 51.04B 2,116B |
Net income | 460M 476M 434M 383M 681M 41.31B 756M 5.17B 1.92B 17.16B 1.78B 1.75B 72.48B | 818M 846M 772M 681M 1.21B 73.43B 1.34B 9.19B 3.41B 30.51B 3.17B 3.11B 129B |
Net Debt | 2.85B 2.95B 2.69B 2.37B 4.22B 256B 4.68B 32.01B 11.88B 106B 11.04B 10.82B 449B | 2.51B 2.6B 2.37B 2.09B 3.72B 226B 4.13B 28.23B 10.48B 93.7B 9.74B 9.55B 396B |
Date | Price | Change | Volume |
---|---|---|---|
11/02/25 | 100.50 CHF | +4.75% | 857,425 |
10/02/25 | 95.94 CHF | +0.52% | 303,506 |
07/02/25 | 95.44 CHF | -0.46% | 345,546 |
06/02/25 | 95.88 CHF | -0.42% | 333,802 |
05/02/25 | 96.28 CHF | -0.12% | 323,531 |
End-of-day quote Euronext Amsterdam, February 10, 2025
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DSFIR Stock

MarketScreener is also available in this country: United States.
Switch edition